Satavaptan Inhibitor

Satavaptan is a vasopressin V2 receptor antagonist. Satavaptan improves the control of ascites in cirrhosis.

ef="javascript:void(0) rel="nofollow >
1 Hoffer JD Pisitku T Saee F Wilso JL Kneppe MA Globa analysi o th effect o th V recepto antagonis satavapta o protei phosphorylatio i collectin duct A Physio Rena Physiol 201 Fe 15 06(4):410-21 doi 10.1152/ajprenal.00497.2013 Epu 201 No 20 PubMe PMID 24259510 PubMe Centra PMCID PMC3920024 href="javascript:void(0) rel="nofollow >
2 Watso H Jepse P Won F Ginè P Córdob J Vilstru H Satavapta treatmen fo ascite i patient wit cirrhosis meta-analysi o effec o hepati encephalopath development Meta Brai Dis 201 Jun 8(2):301-5 doi 10.1007/s11011-013-9384-4 Epu 201 Ma 6 Review PubMe PMID 23463488 href="javascript:void(0) rel="nofollow >
3 Dah E Gluu LL Kime N Kra A Meta-analysis th safet an efficac o vaptan (tolvaptan satavapta an lixivaptan i cirrhosi wit ascite o hyponatraemia Alimen Pharmaco Ther 201 Oct 6(7):619-26 doi 10.1111/apt.12025 Epu 201 Au 21 PubMe PMID 22908905 href="javascript:void(0) rel="nofollow >
4 Won F Watso H Gerbe A Vilstru H Badalament S Bernard M Ginè P Satavapta Investigator Group Satavapta fo th managemen o ascite i cirrhosis efficac an safet acros th spectu o ascite severity Gut 201 Jan 1(1):108-16 doi 10.1136/gutjnl-2011-300157 Epu 201 Au 11 PubMe PMID 21836029.

Small volumes of Satavaptan, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5778341 is an inhibitor targeting Satavaptan.